4//SEC Filing
MOLINA ARTURO MD 4
Accession 0001104659-24-123809
CIK 0001377121other
Filed
Nov 26, 7:00 PM ET
Accepted
Nov 27, 7:11 PM ET
Size
20.4 KB
Accession
0001104659-24-123809
Insider Transaction Report
Form 4
MOLINA ARTURO MD
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2024-11-26$8.04/sh+5,529$44,453→ 51,973 total - Exercise/Conversion
Stock Option (right to buy)
2024-11-27−16,000→ 95,971 totalExercise: $8.04Exp: 2032-11-15→ Common Stock (16,000 underlying) - Sale
Common Stock
2024-11-27$44.50/sh−10,000$445,000→ 46,444 total - Exercise/Conversion
Stock Option (right to buy)
2024-11-26−5,529→ 121,971 totalExercise: $8.04Exp: 2032-11-15→ Common Stock (5,529 underlying) - Sale
Common Stock
2024-11-26$45.60/sh−5,529$252,122→ 46,444 total - Exercise/Conversion
Common Stock
2024-11-27$8.04/sh+10,000$80,400→ 56,444 total - Exercise/Conversion
Common Stock
2024-11-27$8.04/sh+16,000$128,640→ 62,444 total - Sale
Common Stock
2024-11-27$44.83/sh−16,000$717,280→ 46,444 total - Exercise/Conversion
Stock Option (right to buy)
2024-11-27−10,000→ 111,971 totalExercise: $8.04Exp: 2032-11-15→ Common Stock (10,000 underlying)
Footnotes (4)
- [F1]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.94. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $43.80 to $44.92. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.50 to $44.99. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F4]The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer.
Documents
Issuer
Protagonist Therapeutics, Inc
CIK 0001377121
Entity typeother
Related Parties
1- filerCIK 0001398940
Filing Metadata
- Form type
- 4
- Filed
- Nov 26, 7:00 PM ET
- Accepted
- Nov 27, 7:11 PM ET
- Size
- 20.4 KB